The 36-month beta value for ADMA is at 0.44. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 219.42M, and currently, shorts hold a 3.64% of that float. The average trading volume for ADMA on April 10, 2024 was 2.74M shares.
ADMA) stock’s latest price update
The stock of Adma Biologics Inc (NASDAQ: ADMA) has decreased by -1.77 when compared to last closing price of 6.22. Despite this, the company has experienced a -5.12% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-09 that Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.
ADMA’s Market Performance
ADMA’s stock has fallen by -5.12% in the past week, with a monthly drop of -3.63% and a quarterly rise of 27.03%. The volatility ratio for the week is 3.46% while the volatility levels for the last 30 days are 3.49% for Adma Biologics Inc The simple moving average for the last 20 days is -3.05% for ADMA stock, with a simple moving average of 39.85% for the last 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at 5.93% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.62% of loss for the given period.
Volatility was left at 3.49%, however, over the last 30 days, the volatility rate increased by 3.46%, as shares sank -1.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.04% upper at present.
During the last 5 trading sessions, ADMA fell by -5.12%, which changed the moving average for the period of 200-days by +57.47% in comparison to the 20-day moving average, which settled at $6.30. In addition, Adma Biologics Inc saw 35.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from ELMS STEVE, who sale 411,829 shares at the price of $6.08 back on Mar 19 ’24. After this action, ELMS STEVE now owns 2,115,671 shares of Adma Biologics Inc, valued at $2,503,920 using the latest closing price.
ELMS STEVE, the Director of Adma Biologics Inc, sale 49,887 shares at $6.01 during a trade that took place back on Mar 18 ’24, which means that ELMS STEVE is holding 2,527,500 shares at $299,821 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.34 for the gross margin
The net margin for Adma Biologics Inc stands at -0.13. The total capital return value is set at 0.08. Equity return is now at value -19.67, with -8.33 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is 0.86.
Currently, EBITDA for the company is 29.96 million with net debt to EBITDA at 3.11. When we switch over and look at the enterprise to sales, we see a ratio of 5.75. The receivables turnover for the company is 9.42for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.16.
Conclusion
In conclusion, Adma Biologics Inc (ADMA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
